Craig Cocchio, PharmD
Controversy surrounding early goal-directed therapy in septic shock has heightened with the publication of the ARISE trial.
For the first time, one antiplatelet agent has been recommended over another for non"ST-segment elevation acute coronary syndrome.
When association is association and causation is causation.
There was a time when drugs were believed to be unable to cross the placenta, as if it were some impenetrable fortress.
The iPhone Health App provides a new tool for patients to keep track of important medical information that first responders can access.
When trimethoprim/sulfamethoxazole is concomitantly administered with other potassium-sparing diuretics or inhibitors of the renin-angiotensin system, drug interaction notifications alert pharmacists to the potential of hyperkalemia.
Andexanet alfa showed promise as an anti-Xa reversal agent in new research presented at the American Heart Association's Scientific Session 2014.
Evidence released by the manufacturers of Tamiflu and Relenza has raised questions concerning the drugs' efficacy and safety.
Evidence suggesting that this year's flu vaccine missed the mark has caused the CDC to turn to other treatment strategies.
Changes to the prescribing information for alteplase (Activase) recently flew in under the radar.
Despite the most recent meta-analysis published this week in the British Medical Journal, digoxin use in atrial fibrillation remains limited.
The BRIDGE trial proposed that foregoing bridging entirely would be non-inferior to bridge therapy with dalteparin in patients taking warfarin for atrial fibrillation.
+ Load More